Watson, Actavis receive second FTC request
PARSIPPANY, N.J. — Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker’s pending acquisition of Actavis Group.
The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Watson and Actavis have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC.
Watson said it intends to cooperate fully with the FTC’s review and continues to expect the transaction to close in fourth quarter 2012.
Acosta, Wounded Warrior Project announce 2012 Believe in Heroes campaign
JACKSONVILLE, Fla. — Acosta Sales & Marketing and Wounded Warrior Project recently announced that more than 100 companies have signed on to support service members through the Wounded Warrior Project Believe in Heroes campaign, with more brands expected to join the campaign in the coming months.
To date, 53 brands — including Nestle, Brawny and Heinz — and 58 retailers — including, Harris Teeter, Ahold and Supervalu, among others — have signed on to support service members, with more expected to join in the coming months.
Beginning Sept. 11 and running through Veterans Day, each participating brand will offer a high-value coupon in a special, free-standing insert to be circulated to 50 million households nationwide in the Nov. 4 papers. Last year, more than 50 brands and 65 grocery retailers raised $3.5 million for WWP.
For a current list of participating brands, go to Acosta.com/BIH.
Believe in Heroes was founded in 2010 by Acosta to support WWP and make a positive impact on the new generation of veterans.
RxAlly names general counsel, EVP corporate development
LEESBURG, Va. — A coalition of more than 22,000 pharmacies around the country has expanded its leadership team.
RxAlly announced that Tom O’Grady will serve as general counsel and EVP corporate development for the alliance. RxAlly said O’Grady brings more than 30 years of corporate and transactional law experience to his role as general counsel, and in his corporate development role, O’Grady will be structuring business relationships between RxAlly and the companies and businesses that RxAlly will be working with as it continues to align pharmacies and pharmacists, the patients they serve, and the payer community.
O’Grady joins RxAlly from McGuireWoods LLP, where he focused on transactional law for health care and other technology-enabled companies.
"RxAlly is adding an invaluable asset in Tom O’Grady," RxAlly CEO Bruce Roberts saod. "His work in helping to establish RxAlly as our external General Counsel was invaluable. His experience in structuring transactions to achieve aligned business goals is going to be important to us at RxAlly as we focus on how America’s pharmacies will deliver better health to patients, aligning the interests of patients, payers and providers."